Drug · DIN 02523191
IXIFI
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 1, 2025; first marketed April 1, 2025.
- Drug Identification Number (DIN)
- 02523191
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Infliximab L04AB02
- Class
- Human
- Record last updated
- August 7, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| INFLIXIMAB | 100 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 21, 2021: NOC 27276New Drug Submission (NDS)